1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial

CIPN is a common, dose-limiting side effect of taxane-based chemotherapy. Currently there no established strategy for prevention or treatment. Smaller studies suggest that cooling compression could have preventive effect. In this randomized trial we investigated the effectiveness one-sided hand-cooling CIPN. 122 breast cancer patients who received weekly (nab-)paclitaxel-based (neo-)adjuvant chemotherapy were 1:1 to either dominant hand. No intervention was performed on other Cooling with frozen glove (Elasto-Gel; 84400APT Cedex, Akromed), applied by two surgical gloves (one size smaller than tight-fitting size) 30 minutes before, during and after taxane therapy. The primary endpoint efficacy prevent grade ≥2 sensory polyneuropathy evaluated Common Terminology Criteria Adverse Events v4.0 (CTCAE). second hierarchical test, rates between both groups compared. further assessed Total Neuropathy Score (TNSc), patient self-report questionnaires (EORTC-QLQ-CIPN20), MR-neurography (n=21) nerve conduction studies. Additionally, onycholysis, skin toxicity, quality life, CIPN-associated dose-reductions, treatment discontinuations potential risk factors. highly effective in preventing (cooling: 25 vs. 46%; p-value=0.0008; compression: 23 39%; p-value=0.0016) similar (no significant difference found: p-value=0.7303). sensitive detecting showing increased T2 nerve-to-muscle signal ratio indicating edematous changes. Updated results will be presented. POLAR first compare Both interventions almost halved These findings play an important role beyond gynecological oncology.